FDA — authorised 22 October 2020
- Marketing authorisation holder: GILEAD SCIENCES INC
- Status: approved
🇺🇸 Veklury in United States
FDA authorised Veklury on 22 October 2020
Marketing authorisations
FDA — authorised 19 December 2024
- Application: NDA214787
- Marketing authorisation holder: GILEAD SCIENCES INC
- Indication: Labeling
- Status: approved
GILEAD SCIENCES INC received marketing authorisation for Veklury from the FDA on 2024-12-19. The application number for this approval is NDA214787. The marketing authorisation holder is GILEAD SCIENCES INC, and the drug's indication is listed in the labelling.
Veklury in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in United States
Frequently asked questions
Is Veklury approved in United States?
Yes. FDA authorised it on 22 October 2020; FDA authorised it on 19 December 2024.
Who is the marketing authorisation holder for Veklury in United States?
GILEAD SCIENCES INC holds the US marketing authorisation.